Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Boladeras, A.; Martinez, E.; Ferrer, F.; Gutiérrez, Cristina; Villà, Salvador; Pera, J.; Guedea, Ferrán

doi:10.1016/j.rpor.2015.12.002

Cited by 14 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ability to predict clinical outcome is essential to implement optimal strategies to treat these patients. 14,15,20,21 In this study, we demonstrate the CCP and Ki-67 derived from the diagnostic biopsy have prognostic clinical information on aggressiveness, BF, OS, and DSM after primary RT. These results are comparable with previous reports on Ki-67 and CCP genes expression studied separately.…”

Section: Discussionmentioning

confidence: 68%

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

López

Parada

Gallardo

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

a b s t r a c tObjectives: Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness.The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT).Methods: CCP score and Ki-67 were derived retrospectively from pre-treatment paraffinembedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006.

show abstract

Section: Discussionmentioning

confidence: 68%

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

López

Parada

Gallardo

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Данный белок участ-вует во всех фазах активного клеточного цикла (кроме покоящейся фазы S0). Положительная экспрессия белка в ядрах опухолевых клеток эпителиального происхождения позволяет определить степень пролиферативной активности [8][9][10]. Данный показатель применяется в рутинной практике при исследовании рака молочной железы, он позволяет не только прогнозировать течение, но и является достоверным маркером эффективности неоадъювантной терапии [11,12].…”

Section: онкология научная статьяunclassified

Immunohistochemical Study of Tumor Cells Proliferative Activity at Different Graduations of Prostate Cancer

Kudryavtsev

Кудрявцев²,

Kudryavtseva

et al. 2019

Vestn. Ross. univ. družby nar., Ser. Med.

View full text Add to dashboard Cite

Prostate cancer is one of the leading causes of men death in developed countries. Modern diagnostic methods, including a puncture biopsy of the prostate gland, make it possible to verify oncology in the early stages, however, routine studies do not always allow to predict the course of the disease and outcome. The aim of our study was to analyze the clinical, morphological and immunohistochemical features of the proliferative activity of adenocarcinoma cells using the Ki-67 marker, to compare the degree of proliferative activity in tumors of various degrees of malignancy (according to Gleason’s classification), as well as to compare this indicator with the clinical stage of the disease, the level of prostate-specific antigen in the blood, the size of the prostate gland. Materials and Methods: On the basis of the City Clinical Hospital No. 31 and the Veteran Hospital No. 2, paraffin blocks with material obtained as a result of prostate biopsy, transurethral resection, and radical prostatectomy were selected. A morphological and immunohistochemical study of the material with the Ki-67 marker and a quantitative assessment of the degree of proliferative activity were carried out. Data were analyzed using the STATISTICA 10.0 program using estimates of the normality of the data distribution according to the Shapiro-Wilk W-test, the significance of differences was estimated using the Mann-Whitney U-test, and correlation relationships using Spearman’s correlation coefficient. Results: Statistically significant differences in the degree of proliferative activity in groups differing in the degree of differentiation were revealed. A statistically significant direct correlation of moderate severity was revealed when comparing proliferative activity with the degree of differentiation according to the Gleason system (rs = 0.523) and the clinical stage of the disease (rs = 0.646). No statistically significant correlation was found between indicators such as prostate-specific antigen level, age, prostate volume, and proliferative activity index. Conclusion: taking into account the proliferative activity index in addition to clinical and morphological studies helps to diagnose and subsequently predict the course of prostate cancer.

show abstract

“…Using three-dimensional conformal EBRT with dose of greater than 76 Gy as mono-therapy, biochemical failure free survival rates for low risk patients have been reported to be 94% and 81% at 5 and 10 years, respectively, and 86% and 71% for intermediate risk patients [7]. The Phoenix criteria of 'American Society for Therapeutic Radiology and Oncology (ASTRA II)' of a PSA serum level of 2 ng/ml over the PSA nadir obtained after radiotherapy being used to define treatment failure [8].…”

Section: Introductionmentioning

confidence: 99%

The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy

Murray

Aedo

Fuentealba

et al. 2020

ecancer

View full text Add to dashboard Cite

Introduction: External beam radiotherapy is a treatment option for clinically localised prostate cancer; however, some 15% of patients will undergo treatment failure within 5 years. The objective was to compare the Cancer of the Prostate Risk Assessment (CAPRA) score (based on the clinical-pathological findings) and the sub-types of minimal residual disease (MRD) (based on the biological properties of the cancer cells) risk classifications to predict biochemical failure (BF) after external beam radiotherapy. Methods and Patients: Clinical-pathological findings were obtained from the prostate biopsy to determine the CAPRA score and used to define low-, intermediate-and high-risk patients. Blood and bone marrow were obtained 3 months after radiotherapy; circulating prostate cells (CPCs) and micro-metastasis were detected using immunocytochemistry with anti-prostate specific antigen. CPCs and micro-metastasis were classified as positive if at least one cell was detected in the sample. Three subgroups were formed Group A (MRD negative), Group B (micro-metastasis positive, CPC negative) and Group C (CPC positive) Patients were followed up for 10 years or until biochemical failure. Biochemical failure free survival (BFFS) curves were constructed using Kaplan-Meier (observed), a flexible parameter model (predicted survival) and the restricted mean survival time (RMST) was calculated for each subgroup. Results: 309 men participated with a median follow-up of 8 years. The risk of biochemical failure increased proportionally with increasing CAPRA score, hazard ratio 1.18 for intermediate and 1.69 for high risk patients. After 10 years, the percentage BFFS and RMST to failure were 74%, 49%, 16% and 9, 7 and 6 years, respectively. The agreement between observed and predicted BFFS was acceptable (Harrell´s C 0.62). The BFFS curves for MRD were different and not proportional, survival curves for men MRD negative and only micro-metastasis were similar up to 5 years, and then there was increasing failure in the micro-metastasis only group. After 10 years, the percentage BFFS and RMST to failure were 95%, 59%, 28% and 10, 9 and 6 years, respectively. The CAPRA score failed to distinguish between Groups A and B, one third of high risk Group C had low risk CAPRA scores. The agreement between observed and predicted BFFS was very good (Harrell´s C 0.92). Minimal residual disease hazard ratios were Group B 1.84 and Group C 4.51. Research

show abstract

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Cited by 14 publications

References 26 publications

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

Immunohistochemical Study of Tumor Cells Proliferative Activity at Different Graduations of Prostate Cancer

The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy

Contact Info

Product

Resources

About